Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 19/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30992903 | 0.88 | CREBBP (0.41) | CREBBPBRD4MAPT | |
| SCHEMBL30480876 | 0.82 | OTUD7B (0.42) | CREBBPBRD4MAPT | |
| SCHEMBL26112159 | 0.82 | OTUD7B (0.42) | CREBBPBRD4MAPT | |
| SCHEMBL30480867 | 0.82 | OTUD7B (0.48) | MAPT | |
| SCHEMBL30993155 | 0.81 | CREBBP (0.39) | CREBBPBRD4 | |
| SCHEMBL17794572 | 0.79 | CREBBP (0.59) | CREBBPBRD4EP300 | |
| SCHEMBL19368895 | 0.77 | CREBBP (0.58) | CREBBPBRD4 | |
| SCHEMBL22369238 | 0.74 | CREBBP (0.78) | CREBBPBRD4EP300 | |
| SCHEMBL30993509 | 0.74 | GAA (0.40) | MAPT | |
| SCHEMBL30993069 | 0.74 | MAPK1 (0.39) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| WO-2022053967-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | CREBBP 5/4885BRD4 7/4885MAPT 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.